| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/10/2023 | 278.38% | Wedbush | $5 → $7 | Maintains | Outperform |
| 07/27/2023 | 170.27% | Wedbush | → $5 | Reiterates | Outperform → Outperform |
| 01/31/2023 | 170.27% | Wedbush | → $5 | Assumes | → Outperform |
| 10/21/2022 | 170.27% | SVB Leerink | $9 → $5 | Downgrades | Outperform → Market Perform |
| 09/19/2022 | 1305.41% | HC Wainwright & Co. | → $26 | Assumes | → Buy |
| 08/08/2022 | 1791.89% | Aegis Capital | $40 → $35 | Maintains | Buy |
| 06/03/2022 | 386.49% | SVB Leerink | $45 → $9 | Maintains | Outperform |
| 05/18/2022 | 2008.11% | Piper Sandler | $71 → $39 | Maintains | Overweight |
| 09/07/2021 | 1251.35% | HC Wainwright & Co. | $40 → $25 | Maintains | Buy |
| 04/15/2021 | 2872.97% | Aegis Capital | → $55 | Initiates Coverage On | → Buy |
| 03/24/2021 | 2872.97% | JMP Securities | → $55 | Initiates Coverage On | → Market Outperform |
| 10/02/2020 | 2332.43% | SVB Leerink | → $45 | Initiates Coverage On | → Outperform |
| 08/26/2020 | 3737.84% | Piper Sandler | → $71 | Initiates Coverage On | → Overweight |
| 08/21/2020 | 2927.03% | HC Wainwright & Co. | $60 → $56 | Maintains | Buy |
| 08/03/2020 | 3143.24% | HC Wainwright & Co. | $45 → $60 | Maintains | Buy |
| 07/20/2020 | 2062.16% | BMO Capital | → $40 | Initiates Coverage On | → Outperform |
| 06/05/2020 | 3089.19% | Wedbush | → $59 | Initiates Coverage On | → Outperform |
| 05/11/2020 | 2332.43% | HC Wainwright & Co. | → $45 | Initiates Coverage On | → Buy |
| 08/12/2019 | 2062.16% | Chardan Capital | → $40 | Initiates Coverage On | → Buy |
| 07/11/2019 | 2062.16% | Chardan Capital | → $40 | Initiates Coverage On | → Buy |
What is the target price for Immunic (IMUX)?
The latest price target for Immunic (NASDAQ: IMUX) was reported by Wedbush on October 10, 2023. The analyst firm set a price target for $7.00 expecting IMUX to rise to within 12 months (a possible 278.38% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Immunic (IMUX)?
The latest analyst rating for Immunic (NASDAQ: IMUX) was provided by Wedbush, and Immunic maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Immunic (IMUX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunic was filed on October 10, 2023 so you should expect the next rating to be made available sometime around October 10, 2024.
Is the Analyst Rating Immunic (IMUX) correct?
While ratings are subjective and will change, the latest Immunic (IMUX) rating was a maintained with a price target of $5.00 to $7.00. The current price Immunic (IMUX) is trading at is $1.85, which is out of the analyst's predicted range.